格隆汇9月29日丨国新健康(000503.SZ)公布，接到控股股东中海恒实业发展有限公司（简称"中海恒"） 及其一致行动人国新发展投资管理有限公司（简称"国新发展"）出具的《关于增持国新健康股份计划实 施完成的告知函》，中海恒和国新发展于2025年9月26日完成增持计划。截至本公告披露日，本次增持 计划已实施完毕。中海恒和国新发展自2025年9月17日至2025年9月26日通过深圳证券交易所系统以集中 竞价交易方式累计增持公司股份9,481,167股，占公司总股本的0.97%，增持总金额约为人民币 100,001,225.92元（不含交易费用）。 ...

证券简称：国新健康 证券代码：000503 编号：2025-55 国新健康保障服务集团股份有限公司 关于控股股东及其一致行动人增持股份计划实施完成的公告 近日，国新健康保障服务集团股份有限公司（以下简称"公司"）接到控股 股东中海恒实业发展有限公司（以下简称"中海恒"）及其一致行动人国新发展 投资管理有限公司（以下简称"国新发展"）出具的《关于增持国新健康股份计 划实施完成的告知函》，中海恒和国新发展于 2025 年 9 月 26 日完成增持计划， 现将具体情况公告如下： 一、增持主体的基本情况 （一）增持主体 1、中海恒实业发展有限公司 2、国新发展投资管理有限公司 （二）本次增持计划实施前，中海恒直接持有公司无限售股股份 235,702,593 股，占公司总股本的 24.02%。国新发展直接持有公司限售股股份 24,123,980 股， 占公司总股本的 2.46%。上述两个增持主体合计持有公司股份 259,826,573 股， 合计占公司总股本的 26.48%。 （三）公司于 2025 年 4 月 8 日披露了《关于控股股东及其一致行动人增持 股份计划的公告》（公告编号：2025-16），截至 2025 ...

格隆汇9月19日丨国新健康(000503.SZ)公布，2025年9月19日，公司收到国新发展出具的《关于增持国 新健康股份的告知函》。国新发展于2025年9月17日至2025年9月19日通过深圳证券交易所交易系统以集 中竞价交易方式累计增持公司股份7,681,327股，占公司总股本的0.78%，成交总金额为人民币 81,146,136.12元（不含交易费用等）。 ...

证券简称：国新健康 证券代码：000503 编号：2025-54 国新健康保障服务集团股份有限公司 关于控股股东及其一致行动人增持股份权益变动触及 1%整倍数 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、增持计划的基本情况 2 2025 年 4 月 8 日，国新健康保障服务集团股份有限公司（以下简称"公司" 或"国新健康"）披露了《关于控股股东及其一致行动人增持股份计划的公告》， 基于对公司未来高质量发展的信心以及公司价值的认可，公司控股股东中海恒实 业发展有限公司（以下简称"中海恒"）及其一致行动人国新发展投资管理有限 公司（以下简称"国新发展"）计划在未来 6 个月内，通过集中竞价等深圳证券 交易所允许的方式增持国新健康股份，拟增持金额不低于人民币 1 亿元，不超过 人民币 2 亿元。 具体内容详见公司于 2025 年 4 月 8 日在《中国证券报》《上海证券报》《证 券时报》及巨潮资讯网（网址：www.cninfo.com.cn）披露的《关于控股股东及 其一致行动人增持股份计划的公告》（公告编号：2025-16）。 二、股东权益变动情况 ...

国新健康公告，国新发展于2025年9月17日至2025年9月19日通过集中竞价累计增持768.13万股，占公司 总股本0.78%，成交金额8114.61万元；增持后其持股3180.53万股，占3.24%，中海恒及其一致行动人合 计持股2.68亿股，占27.26%，本次权益变动触及1%整数倍，增持计划仍在实施。 ...

Core Insights - The company held a performance briefing for the first half of 2025, discussing operational results and future plans, focusing on AI commercialization, digital healthcare, and cost reduction strategies [1] - The company achieved a revenue of 95.53 million yuan in the reporting period, optimizing its business structure and maintaining a leading position in the digital healthcare sector [2] Group 1: Business Performance - In the first half of 2025, the company actively responded to market changes and optimized its business structure, focusing on the integration of healthcare, medical insurance, and pharmaceuticals [1] - The company’s revenue reached 95.53 million yuan, with significant achievements in digital medical insurance, including winning a bid for a drug procurement subsystem project worth 10.66 million yuan [2] - The company holds a market share of 40.5% in payment methods and 17.4% in fund supervision, leading the industry in bid-winning scale [2] Group 2: Strategic Focus - The company is concentrating on four core business areas: comprehensive management of medical insurance funds, medical quality and safety services, drug and device regulation, and innovative health services [1] - In the second half of 2025, the company aims for steady revenue growth and cost reduction, focusing on AI model empowerment, deepening data application, and advancing comprehensive reforms [2] - The company is accelerating its AI transformation in the digital healthcare sector, launching core products like Intelligent Review 2.0 and promoting a smart service ecosystem in disease prevention and control [2]

Group 1 - The software development sector experienced a decline of 2.21% on September 18, with *ST Dongtong leading the drop [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] - Notable gainers in the software development sector included Xinghuan Technology, which rose by 7.65% to a closing price of 62.76, and Xinan Century, which increased by 7.42% to 15.50 [1] Group 2 - *ST Dongtong saw a significant decline of 19.88%, closing at 2.70, with a trading volume of 112,900 shares [2] - The sector experienced a net outflow of 7.379 billion yuan from institutional funds, while retail investors contributed a net inflow of 5.749 billion yuan [2] - Major stocks that faced declines included Anbotong, which fell by 8.92% to 67.68, and Dazhihui, which decreased by 8.83% to 15.48 [2]

9月18日，国新健康涨5.37%，截至发稿，报10.80元/股，成交1.97亿元，换手率1.90%，总市值105.98亿 元。 资料显示，国新健康保障服务集团股份有限公司位于北京市东城区沙滩后街22号院2号楼、3号楼，成立 日期1987年8月28日，上市日期1992年11月30日，公司主营业务涉及医药电子商务、医疗福利管理等。 主营业务收入构成为：数字医保52.03%，数字医药26.17%，数字医疗17.70%，健康服务4.01%，房屋租 赁0.09%。 华夏中证1000ETF（159845）基金经理为赵宗庭。 截至发稿，赵宗庭累计任职时间8年157天，现任基金资产总规模3891.48亿元，任职期间最佳基金回报 116.15%， 任职期间最差基金回报-32.63%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从国新健康十大流通股东角度 数据显示，华夏基金旗下1只基金位居国新健康十大流通股东。华夏中证1000ETF（159845）二季度新 进十大流 ...

Core Insights - GuoXin Health successfully held a performance briefing for the first half of 2025, highlighting its operational achievements and future plans [1][2] - The management team engaged in discussions regarding the commercialization of AI models, digital healthcare, and cost reduction strategies [2] Financial Performance - In the first half of 2025, GuoXin Health achieved operating revenue of 95.53 million yuan, with an optimized business structure [5] - The company maintained a leading position in the digital healthcare sector, with a market share of 40.5% in payment methods and 17.4% in fund supervision [5] Business Development - GuoXin Health expanded its services across 200 regions in 29 provinces, focusing on comprehensive management of healthcare funds and quality services [5] - The digital pharmaceutical sector showed strong growth, with successful contracts signed for integrated platforms in Chongqing and Zhejiang [5] Technological Innovation - The company launched the "Tianshu·Three-Med" model and the "Lingxi" intelligent platform, advancing its "AI IN ALL" initiative [6] - GuoXin Health developed a multi-dimensional database system in collaboration with the National Medical Insurance Bureau [6] Operational Efficiency - The company implemented comprehensive reforms to enhance operational efficiency, including optimizing processes and strengthening cost control [6] - Legal compliance has been integrated into decision-making processes, ensuring proper use of raised funds [6] Future Outlook - GuoXin Health aims for steady revenue growth and cost reduction, focusing on AI model empowerment and deepening data applications [6]

Core Insights - The company held a performance briefing on September 16, 2025, discussing its operational results and future outlook, attended by over 50 institutions and media representatives [1] Group 1: AI Applications - The company established an AI center in the first half of 2025, deploying AI across various sectors including healthcare, which positively impacted performance [2] - AI applications have been implemented in medical insurance, covering over 800 hospitals, and are being upgraded in regions like Xinjiang and Zhejiang [2] - The company aims to build a closed-loop AI capability in the healthcare sector to enhance competitiveness in the medium to long term [2] Group 2: Health Insurance Business - The company is adapting to industry changes driven by new national policies, focusing on risk control and product innovation in health insurance services [3] - Collaborations with multiple insurance companies have been established to enhance the full-chain service of health insurance [3] Group 3: Digital Healthcare and Medical Business - The company sees a positive outlook for digital healthcare and medical services, supported by ongoing policy backing and strong demand for medical insurance services [4] - Digital healthcare is expected to introduce new products, with data operations and AI innovations driving performance growth [4] Group 4: Digital Pharmaceutical Business - The digital pharmaceutical segment experienced high revenue growth in the first half of 2025, with an increase in gross margin due to fixed labor costs [5] - The business is expanding from regulatory services to digital services for pharmaceutical companies, indicating a broad market potential for continued growth [5] Group 5: Chronic Disease Management - The company has established a clear layout for chronic disease management, consisting of a central hub, two major platforms, and three service categories [6] - The business model aims to provide convenient services while exploring sustainable profit paths [6] - The company is addressing reasons for the decline in gross margin and implementing cost control measures to enhance profitability [6]